Evidence map›Paper›PMID 28314136›Full record

ArticleBiomaterials2017

Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis.

Christa L Pawlowski, Wei Li, Michael Sun, Kavya Ravichandran, DaShawn Hickman, Clarissa Kos, Gurbani Kaur, Anirban Sen Gupta

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 160 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Engineered Probiotic-Powered Micro-Rod Robot Bomb for Thrombus-Penetrating Explosion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Review
  11. Targeted delivery of peptide functionalized nanoparticles for ameliorating myocardial infarction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Christa L PawlowskiCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA.
Wei LiCleveland Clinic Foundation, Department of Cellular and Molecular Medicine, Cleveland, OH 44195, USA.
Michael SunCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA.
Kavya RavichandranHathaway Brown School, Shaker Heights, OH 44122, USA.
DaShawn HickmanCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA.
Clarissa KosCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA.
Gurbani KaurHathaway Brown School, Shaker Heights, OH 44122, USA.
Anirban Sen GuptaCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA. Electronic address: axs262@case.edu.
Case Western Reserve University · USShaker Heights Public Library · USCleveland Clinic · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
Clinical and Translational Science Collaborative of ClevelandTL1TR000441 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$2.8M
Platelet-inspired Delivery System for Targeted Thrombolytic TherapyR01HL129179 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SEN GUPTA, ANIRBAN · 2015 to 2018
$1.8M
NCATS NIH HHS TL1 TR002549NHLBI NIH HHS R01 HL129179NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Intravascular administration of plasminogen activators is a clinically important thrombolytic strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic off-target drug action, which affects hemostatic capabilities and causes substantial hemorrhagic risks. This issue can be potentially resolved by designing technologies that allow thrombus-targeted delivery and site-specific action of thrombolytic drugs. To this end, leveraging a liposomal platform, we have developed platelet microparticle (PMP)-inspired nanovesicles (PMINs), that can protect encapsulated thrombolytic drugs in circulation to prevent off-target uptake and action, anchor actively onto thrombus via PMP-relevant molecular mechanisms and allow drug release via thrombus-relevant enzymatic trigger. Specifically, the PMINs can anchor onto thrombus via heteromultivalent ligand-mediated binding to active platelet integrin GPIIb-IIIa and P-selectin, and release the thrombolytic payload due to vesicle destabilization triggered by clot-relevant enzyme phospholipase-A

Indexed as

FibrinolysisAnimalsBlood PlateletsCell-Derived MicroparticlesFibrinolytic AgentsIntravital MicroscopyLipaseMaleMice, Inbred C57BLNanomedicinePeptidesPhospholipases A2SolubilityThrombosisFibrinolytic AgentsLipasePeptidesPhospholipases A2Drug deliveryEnzyme-triggered releaseLipid vesicleNanomedicinePlatelet-derived microparticleTargeted thrombolysis

Identifiers

PMID28314136
PMCPMC6526940
OpenAlexW2601903984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.